Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis
Shots:
- The EC’s approval is based on data from DELIVER and REFINE studies evaluating the efficacy- PK- and PD of Tysabri (300mg- SC- q4w) vs Tysabri (300mg- IV- q4w) in patients with RRMS
- The results demonstrated that the Tysabri (SC) in both studies showed clinical benefits and well-characterized safety profile. The SC option expands the clinical settings while safety is consistent with IV formulation in other clinical studies and the post-marketing setting
- Tysabri is the only high-efficacy MS therapy to offer two routes of administration options thus- providing flexibility to meet patients' individual preferences and needs
Ref: GlobeNewswire | Image: Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com